Results 61 to 70 of about 9,966 (258)

Pharmacovigilance‐Based Identification and Mechanistic Exploration of Periodontitis‐Related Drugs

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Background Periodontitis is a common chronic inflammatory disease. However, drug‐related risks and underlying molecular mechanisms remain underexplored from large real‐world data. Methods We first mined the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify drugs disproportionately associated with ...
Wuda Huoshen, Junkai Xiong, Xunmi Ma, Heng Wang, Panyu Cheng, Xinyu Chen, Ge Shuai, Yi Chen, Xinyue Zhang, Chen Sun, Chunhui Li, Rui Shi   +11 more
wiley   +1 more source

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

Alzheimer’s Research & Therapy
A recent paper published a lecanemab analysis with data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Michael Irizarry, Ilona Surick, Ari Michael, Lynn D. Kramer   +3 more
doaj   +1 more source

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
ObjectiveOmadacycline is a newly launched drug of tetracycline. Therefore, it is necessary to comprehensive evaluate reports on the safety of omadacycline in large, real-world populations.
Xueping Shi, Chen Wang, Xiang Liu, Li Zou, Pei Guo   +4 more
doaj   +1 more source

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]

, 2016
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila, Nathan, Kobi T, Werner, Paul M   +2 more
core   +2 more sources

Xerostomia as a Rare Adverse Effect of Low‐Dose Oral Minoxidil: A Case Report With Recurrence After Rechallenge

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Low‐dose oral minoxidil (LDOM) is an emerging option for the treatment of female pattern hair loss (FPHL), generally well tolerated at doses under 1 mg/day. We report a rare adverse event of significant xerostomia in a 74‐year‐old woman with Hashimoto's thyroiditis, receiving 0.5 mg/day of minoxidil for FPHL.
Nicolò Rivetti
wiley   +1 more source

Reassessment of pioglitazone and bladder cancer based on FAERS database

Expert opinion on drug safety
The association between pioglitazone (PLZ) and bladder cancer (BC) remains controversial in several randomized control trials, meta-analyses of multiple prospective studies, and large-scale observational studies. Adverse event (AE) data from 1 January 2004 to 31 March 2024 were extracted from the Food and Drug Administration Adverse Event Reporting ...
Hai-Yan, Chen, Hui, Zhao, Jun-Jie, Yang, Qian, Zhang, Ming-Ming, Yan, Xiao-Yan, Qiu   +5 more
openaire   +2 more sources

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Frontiers in Pharmacology
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Haoxiang Hu, Yunhan Zhao, Jiesheng Mao, Jianghai He, Yihan Zhang, Hongyu Ye, Xiaokai Yang   +6 more
doaj   +1 more source

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights

Clinical and Translational Discovery, Volume 5, Issue 5, October 2025.
Abstract Background Immune checkpoint inhibitors (ICIs) are widely used in childhood cancer, posing challenges with associated ICIs‐related adverse events (irAEs). This study focuses on pediatric irAEs and explores underlying mechanisms. Methods Data on ICI‐related adverse reactions were gathered from two sources: VigiBase database (1967–2023) and the ...
Anqi Lin, Junyi Shen, Zhenyu Xie, Quan Cheng, Jian Zhang, Peng Luo   +5 more
wiley   +1 more source

Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Drug, Healthcare and Patient Safety, 2023
Teresa A Simon,1 John H Simon,1 Erin G Heaning,1 Andres Gomez-Caminero,1 Jahan P Marcu1,2 1Physicians Research Center, LLC, Toms River, NJ, USA; 2Marcu Enterprises, Jersey City, NJ, USACorrespondence: Teresa A Simon, Physicians Research Center, LLC, Toms
Simon TA, Simon JH, Heaning EG, Gomez-Caminero A, Marcu JP   +4 more
doaj  

Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis

Immunity, Inflammation and Disease, Volume 13, Issue 10, October 2025.
A systematic review and meta‐analysis evaluating the effectiveness and safety of Remdesivir and Molnupiravir as treatments for COVID‐19 found no significant differences between the two drugs in mortality, hospitalization, viral clearance rates, or mean viral clearance time.
Seyed Hamid Pakzad Moghadam, Ali Sarkoohi, Zia Navidi, Bahman Amani, Behnam Amani, Saeed Khorramnia   +5 more
wiley   +1 more source